{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:58:28Z","timestamp":1790812708470,"version":"4.1.0"},"reference-count":41,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Das metastasierte klarzellige Nierenzellkarzinom (mRCC) hat in den letzten zwei Jahrzehnten einen grundlegenden therapeutischen Wandel erfahren. Nachdem aufgrund der ausgepr\u00e4gten Chemotherapieresistenz lange nur begrenzt wirksame immunmodulatorische Therapien zur Verf\u00fcgung standen, f\u00fchrte die Einf\u00fchrung VEGF-Rezeptor-gerichteter Tyrosinkinaseinhibitoren (TKI) zu einer deutlichen Verbesserung der klinischen Ergebnisse. Derzeit stellen zielgerichtete Therapien und die neueren Immuncheckpoint-Inhibitoren (ICI) die zentralen S\u00e4ulen der systemischen Behandlung des mRCC dar. Mit diesen Kombinationstherapien konnte das 5-Jahres-\u00dcberleben auf \u00fcber 40 % gesteigert werden, sodass sie heute den Therapiestandard darstellen (CheckMate 214, CheckMate 9ER, CLEAR, KEYNOTE-426). Jedoch besteht weiterhin ein erheblicher therapeutischer Bedarf, insbesondere in den Folgetherapielinien, sodass die Entwicklung neuer therapeutischer Strategien sowie die Pr\u00e4zisierung der Patientenstratifikation zentrale Voraussetzungen f\u00fcr eine Verbesserung der klinischen Outcomes darstellen.<\/jats:p>","DOI":"10.1055\/a-2931-0105","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:57:36Z","timestamp":1790722656000},"source":"Crossref","is-referenced-by-count":0,"title":["Aktuelle Systemtherapie des Metastasierten Nierenzellkarzinoms"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7806-4245","authenticated-orcid":false,"given":"Stefan Alexander","family":"Cieslik","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Essen, Germany","place":["Essen"],"department":["Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Darr","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Essen, Germany","place":["Essen"],"department":["Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Pieperjohanns","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Essen Innere Klinik (Tumorforschung), Germany","place":["Essen"],"department":["Innere Klinik \u2013 Tumorforschung"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut-Ulas","family":"Yesilyurt","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Essen, Germany","place":["Essen"],"department":["Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulham","family":"Al-Nader","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Essen, Germany","place":["Essen"],"department":["Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Wahl","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Essen, Germany","place":["Essen"],"department":["Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Essen, Germany","place":["Essen"],"department":["Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-7687","authenticated-orcid":false,"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Essen, Germany","place":["Essen"],"department":["Carolus Institut f\u00fcr Urologische Onkologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc2502","article-title":"The von Hippel\u2013Lindau tumour suppressor protein: O2 sensing and cancer","volume":"8","author":"Jr Kaelin","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-Inducible Factors in Physiology and Medicine","volume":"148","author":"GL Semenza","year":"2012","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ccr.2007.02.006","article-title":"HIF-2\u03b1 Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity","volume":"11","author":"JD Gordan","year":"2007","journal-title":"Cancer Cell"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/2159-8290.CD-17-0375","article-title":"VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma","volume":"7","author":"X Yao","year":"2017","journal-title":"Cancer Discov"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"7215","DOI":"10.1158\/1078-0432.CCR-06-2254","article-title":"Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma","volume":"12","author":"PH Patel","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma","volume":"356","author":"RJ Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11523-019-00653-5","article-title":"Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data","volume":"14","author":"M Moran","year":"2019","journal-title":"Target Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma","volume":"369","author":"RJ Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"T Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.4103\/crst.crst_151_21","article-title":"Lenvatinib: A narrative drug review","volume":"4","author":"A Goel","year":"2021","journal-title":"Cancer Res Stat Treat"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"RJ Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"RJ Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"DYC Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma","volume":"17","author":"RJ Motzer","year":"2026","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"T Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"TK Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"R Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"NM Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","article-title":"Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial","volume":"36","author":"TK Choueiri","year":"2025","journal-title":"Ann Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study","volume":"42","author":"RJ Motzer","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1200\/JCO.2025.43.5_suppl.439","article-title":"Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial","volume":"43","author":"RJ Motzer","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"BI Rini","year":"2025","journal-title":"Nat Med"},{"key":"ref23","doi-asserted-by":"publisher","article-title":"Plimack ER, Powles T, Stus V, et al. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study. Eur Urol 2023; 84: 449\u2013454","DOI":"10.1016\/j.eururo.2023.06.006"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study","volume":"404","author":"TK Choueiri","year":"2024","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"SK Pal","year":"2023","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"TK Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"BI Rini","year":"2011","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma","volume":"391","author":"TK Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","article-title":"Randomized phase III trial of temsirolimus versus sorafenib as second-line  therapy after sunitinib in patients with metastatic renal cell carcinoma","volume":"32","author":"TE Hutson","year":"2014","journal-title":"J Clin Oncol  Off J Am Soc  Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1200\/JCO.2026.44.7_suppl.442","article-title":"Treatment (Rx) patterns and outcomes with second-line (2L) therapy in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with cabozantinib plus nivolumab (cabo+nivo) or lenvatinib plus pembrolizumab (len+pem) in first-line (1L","volume":"44","author":"E Murdock","year":"2026","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.2026.44.7_suppl.537","article-title":"Circulating KIM-1 and ctDNA as prognostic markers in oligometastatic clear cell renal cell carcinoma (ccRCC): The K-COMPASS model","volume":"44","author":"C Tang","year":"2026","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"A Bartolomucci","year":"2025","journal-title":"npj Precis Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1200\/JCO.2023.41.6_suppl.715","article-title":"Longitudinal detection of circulating tumor DNA in patients with advanced renal cell carcinoma","volume":"41","author":"A Basu","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e2200543","DOI":"10.1200\/PO.22.00543","article-title":"Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma","volume":"7","author":"A Chehrazi-Raffle","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102235","article-title":"High Sensitivity Circulating Tumor-DNA Assays in Renal Cell Carcinoma\u2013Are we there yet?","volume":"22","author":"F Sidhom","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer","volume":"393","author":"T Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.euros.2021.12.006","article-title":"Circulating Tumor DNA in Patients with Renal Cell Carcinoma. A Systematic Review of the Literature","volume":"37","author":"L Geertsen","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","article-title":"[89Zr]Zr-girentuximab for PET\u2013CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","volume":"25","author":"B Shuch","year":"2024","journal-title":"Lancet Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00259-019-04358-9","article-title":"Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET\/CT in patients with newly diagnosed metastatic renal cell carcinoma","volume":"46","author":"SR Verhoeff","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3390\/diagnostics16091323","article-title":"Diagnostic Role and Clinical Impact of Zr-Girentuximab PET-CT for the Diagnosis and Treatment of Clear-Cell Renal Cell Carcinoma","volume":"16","author":"DA Gonz\u00e1lez-Padilla","year":"2026","journal-title":"Diagnostics"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.3390\/cancers15204934","article-title":"Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring","volume":"15","author":"KA Dani","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2931-0105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:34:11Z","timestamp":1790811251000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2931-0105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1055\/a-2931-0105","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}